↓ Skip to main content

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Published in
Journal for Immunotherapy of Cancer, August 2019
DOI 10.1186/s40425-019-0710-1
Pubmed ID
Authors

Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang, Leonard T. Heffner

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 16%
Researcher 7 14%
Student > Ph. D. Student 6 12%
Other 4 8%
Lecturer 3 6%
Other 7 14%
Unknown 15 30%
Readers by discipline Count As %
Medicine and Dentistry 14 28%
Biochemistry, Genetics and Molecular Biology 11 22%
Agricultural and Biological Sciences 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Immunology and Microbiology 2 4%
Other 1 2%
Unknown 15 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2019.
All research outputs
#8,324,921
of 15,864,860 outputs
Outputs from Journal for Immunotherapy of Cancer
#873
of 1,298 outputs
Outputs of similar age
#113,326
of 264,695 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 15,864,860 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,298 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,695 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them